Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells

First-generation bromodomain extra-terminal protein (BETP) inhibitors (BETi) (e.g., OTX015) that disrupt binding of BETP BRD4 to chromatin transcriptionally attenuate AML-relevant progrowth and prosurvival oncoproteins. BETi treatment induces apoptosis of AML BPCs, reduces in vivo AML burden and ind...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Fiskus, Warren, Cai, Tianyu, DiNardo, Courtney D., Kornblau, Steven M., Borthakur, Gautam, Kadia, Tapan M., Pemmaraju, Naveen, Bose, Prithviraj, Masarova, Lucia, Rajapakshe, Kimal, Perera, Dimuthu, Coarfa, Cristian, Mill, Christopher P., Saenz, Dyana T., Saenz, David N., Sun, Baohua, Khoury, Joseph D., Shen, Yu, Konopleva, Marina, Bhalla, Kapil N.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6333829/
https://ncbi.nlm.nih.gov/pubmed/30647404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0165-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados